Alterity Therapeutics Ltd - ADR

Alterity Therapeutics Ltd - ADR

ATHE

Get informed when a big investor buys or sells

+ Follow
Market Cap$87M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Alterity Therapeutics Ltd - ADRAlterity Therapeutics Ltd - ADR-3.2--75%--
$9.00

Target Price by Analysts

230.9% upsideAlterity Therapeutics Target Price DetailsTarget Price
$1.48

Current Fair Value

45.6% downside

Overvalued by 45.6% based on the discounted cash flow analysis.

Share Statistics

Market cap$87.00 Million
Enterprise Value$49.88 Million
Dividend Yield$- (-)
Earnings per Share$-1.32
Beta-0.03
Outstanding Shares18,125,738

Return

Return on Equity-74.85%ROE
Return on Assets-69.49%
Return on Invested Capital-91.65%

Valuation & Multiples

P/E Ratio-3.22P/E Ratio
PEG-1.78PEG
Price to Sales-Price to Sales
Price to Book Ratio1.36Price to Book Ratio
Enterprise Value to Revenue10.76
Enterprise Value to EBIT-1.27
Enterprise Value to Net Income-2
Total Debt to Enterprise0
Debt to Equity0Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
August 28, 2026
EPS Estimate
$-0.12
Average shareholder expectation
Revenue Estimate
$2.32 M
Average shareholder expectation

Next Earnings Call

Expected Date
March 4, 2027
EPS Estimate
$-0.03
Average shareholder expectation
Revenue Estimate
-
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.00000%
Total Calls-
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %2.18%▲ 0.29%
Total Invested$2.12M▲ 89.47%
Investors Holding22▲ 7.00%

ESG Score

No data

About Alterity Therapeutics Ltd

11 employees
CEO: Geoffrey Kempler

Based in Melbourne, Australia, Alterity Therapeutics Limited, founded in 1997, is dedicated to the discovery and advancement of treatments for neurological conditions such as Alzheimer's, Huntington's, and Parkinson's diseases, among oth...